Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.28
AEGR's Cash to Debt is ranked lower than
91% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. AEGR: 0.28 )
Ranked among companies with meaningful Cash to Debt only.
AEGR' s 10-Year Cash to Debt Range
Min: 0.02  Med: 10.06 Max: No Debt
Current: 0.28
Equity to Asset 0.35
AEGR's Equity to Asset is ranked lower than
81% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. AEGR: 0.35 )
Ranked among companies with meaningful Equity to Asset only.
AEGR' s 10-Year Equity to Asset Range
Min: 0.35  Med: 0.79 Max: 0.87
Current: 0.35
0.35
0.87
F-Score: 5
Z-Score: 0.57
M-Score: 152.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -10.75
AEGR's Operating margin (%) is ranked higher than
64% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -71.01 vs. AEGR: -10.75 )
Ranked among companies with meaningful Operating margin (%) only.
AEGR' s 10-Year Operating margin (%) Range
Min: -128.43  Med: -72.65 Max: -16.86
Current: -10.75
-128.43
-16.86
Net-margin (%) -20.67
AEGR's Net-margin (%) is ranked higher than
60% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. AEGR: -20.67 )
Ranked among companies with meaningful Net-margin (%) only.
AEGR' s 10-Year Net-margin (%) Range
Min: -130.51  Med: -77.69 Max: -24.87
Current: -20.67
-130.51
-24.87
ROE (%) -28.62
AEGR's ROE (%) is ranked higher than
52% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -30.92 vs. AEGR: -28.62 )
Ranked among companies with meaningful ROE (%) only.
AEGR' s 10-Year ROE (%) Range
Min: -105.89  Med: -76.69 Max: -28.82
Current: -28.62
-105.89
-28.82
ROA (%) -12.85
AEGR's ROA (%) is ranked higher than
62% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. AEGR: -12.85 )
Ranked among companies with meaningful ROA (%) only.
AEGR' s 10-Year ROA (%) Range
Min: -189.06  Med: -61.99 Max: -14.07
Current: -12.85
-189.06
-14.07
ROC (Joel Greenblatt) (%) -181.41
AEGR's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. AEGR: -181.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AEGR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -88019.35  Med: -24512.59 Max: -897.06
Current: -181.41
-88019.35
-897.06
EBITDA Growth (3Y)(%) -21.90
AEGR's EBITDA Growth (3Y)(%) is ranked lower than
73% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. AEGR: -21.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AEGR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -12.40 Max: 20.3
Current: -21.9
0
20.3
EPS Growth (3Y)(%) -12.70
AEGR's EPS Growth (3Y)(%) is ranked lower than
58% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. AEGR: -12.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AEGR' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -17.20 Max: 1.7
Current: -12.7
0
1.7
» AEGR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AEGR Guru Trades in Q2 2014

Jim Simons 76,500 sh (New)
Michael Price 240,000 sh (+20.00%)
Steven Cohen 923,700 sh (unchged)
» More
Q3 2014

AEGR Guru Trades in Q3 2014

Joel Greenblatt 10,964 sh (New)
George Soros 25,000 sh (New)
Jim Simons 89,000 sh (+16.34%)
Michael Price 240,000 sh (unchged)
Steven Cohen 757,500 sh (-17.99%)
» More
Q4 2014

AEGR Guru Trades in Q4 2014

Steven Cohen 1,854,600 sh (+144.83%)
Steven Cohen 1,549,762 sh (+67.78%)
Steven Cohen 1,854,600 sh (unchged)
Steven Cohen 1,549,762 sh (unchged)
George Soros Sold Out
Joel Greenblatt Sold Out
Michael Price Sold Out
Jim Simons Sold Out
» More
Q1 2015

AEGR Guru Trades in Q1 2015

Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AEGR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 25.25
AEGR's Forward P/E is ranked lower than
55% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 23.87 vs. AEGR: 25.25 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.25
AEGR's P/B is ranked higher than
62% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: 4.68 vs. AEGR: 3.25 )
Ranked among companies with meaningful P/B only.
AEGR' s 10-Year P/B Range
Min: 3.25  Med: 9.00 Max: 24.68
Current: 3.25
3.25
24.68
P/S 2.64
AEGR's P/S is ranked higher than
83% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.51 vs. AEGR: 2.64 )
Ranked among companies with meaningful P/S only.
AEGR' s 10-Year P/S Range
Min: 2.63  Med: 16.08 Max: 1820.75
Current: 2.64
2.63
1820.75
POCF 217.89
AEGR's POCF is ranked lower than
91% of the 201 Companies
in the Global Biotechnology industry.

( Industry Median: 34.67 vs. AEGR: 217.89 )
Ranked among companies with meaningful POCF only.
AEGR' s 10-Year POCF Range
Min: 217.89  Med: 277.88 Max: 349.25
Current: 217.89
217.89
349.25
Current Ratio 3.63
AEGR's Current Ratio is ranked lower than
56% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. AEGR: 3.63 )
Ranked among companies with meaningful Current Ratio only.
AEGR' s 10-Year Current Ratio Range
Min: 0.03  Med: 8.42 Max: 17.43
Current: 3.63
0.03
17.43
Quick Ratio 2.47
AEGR's Quick Ratio is ranked lower than
65% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. AEGR: 2.47 )
Ranked among companies with meaningful Quick Ratio only.
AEGR' s 10-Year Quick Ratio Range
Min: 0.03  Med: 8.38 Max: 17.43
Current: 2.47
0.03
17.43
Days Inventory 234.52
AEGR's Days Inventory is ranked lower than
79% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 116.21 vs. AEGR: 234.52 )
Ranked among companies with meaningful Days Inventory only.
AEGR' s 10-Year Days Inventory Range
Min: 59.63  Med: 100.62 Max: 141.61
Current: 234.52
59.63
141.61
Days Sales Outstanding 38.41
AEGR's Days Sales Outstanding is ranked higher than
72% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.10 vs. AEGR: 38.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
AEGR' s 10-Year Days Sales Outstanding Range
Min: 39.47  Med: 48.20 Max: 56.93
Current: 38.41
39.47
56.93

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.16
AEGR's Price/Median PS Value is ranked higher than
96% of the 539 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. AEGR: 0.16 )
Ranked among companies with meaningful Price/Median PS Value only.
AEGR' s 10-Year Price/Median PS Value Range
Min: 0.23  Med: 1.11 Max: 62.06
Current: 0.16
0.23
62.06
Earnings Yield (Greenblatt) (%) -3.35
AEGR's Earnings Yield (Greenblatt) (%) is ranked higher than
60% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. AEGR: -3.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AEGR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -7.7  Med: 0.00 Max: 0
Current: -3.35
-7.7
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:KYE.Germany,
Aegerion Pharmaceuticals, Inc. was incorporated in February 2005. The Company is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company currently operates in one business segment focusing on the development and commercialization of its product, lomitapide. The product, lomitapide, received marketing approval, under the brand name JUXTAPID (lomitapide) capsules ("JUXTAPID"). It is an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein ("LDL") apheresis where available, to reduce low-density lipoprotein cholesterol ("LDL-C"), total cholesterol ("TC"), apolipoprotein B ("apo B") and non-high-density lipoprotein cholesterol ("non-HDL-C") in adult patients with homozygous familial hypercholesterolemia ("HoFH"). Lomitapide is also approved for the treatment of HoFH in Norway, Iceland, Mexico and Canada. The Company also sells lomitapide, on a named patient basis, in Brazil and in a limited number of other countries outside the U.S. and the EU where such sales are authorized based on the U.S. or the EU approval. The Company also launched JUXTAPID in the U.S. The Company relies on a contract manufacturer to produce drug substance for lomitapide and another contract manufacturer for drug product for its clinical trials and for commercial supplies. It distributes JUXTAPID through a specialty pharmacy that distributes JUXTAPID directly to patients and, under limited circumstances, to other purchasers. The lomitapide patent portfolio consists of five issued U.S. patents and issued patents in Europe, Canada, Israel, Australia, New Zealand and Japan and pending applications in the U.S., Australia, Japan, Canada, India and South Korea, all of which have been licensed in a specific field. The Company competes with Regeneron Pharmaceuticals, Inc., in collaboration with Sanofi, Roche Holding AG, Pfizer Inc., Amgen Inc., and Alnylam Pharmaceuticals, Inc. The Company's operations are subject to federal, state and local level, the EU and other countries extensively regulations.
» More Articles for AEGR

Headlines

Articles On GuruFocus.com
Gilead Sciences Releases Impressive Results for Hepatitis C Drug Nov 12 2014 
Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 
Weekly CEO Buys Highlight: GEO, TRUE, BANC, AEGR, CLMS Jun 02 2014 
Three CEOs Reporting Large Insider Buys May 22 2014 
Four CEOs Reporting Large Insider Buys May 09 2014 
100 Stocks at All-Time Highs | 60 Dividend Stocks Below the Results Feb 19 2013 
My 3 Favorite Dividend Stocks at All-Time-Highs | Stock List Dec 27 2012 
Weekly CFO Buys Highlight: RXN, XBKS, STAG, AEGR, PZG Apr 02 2012 

More From Other Websites
Aegerion Pharma downgraded by Guggenheim Jul 06 2015
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 29 2015
Notable option activity in equities Jun 29 2015
Aegerion Pharmaceuticals Appoints Gregory Perry as Chief Financial Officer Jun 25 2015
Aegerion Pharmaceuticals Appoints Gregory Perry as CFO Jun 25 2015
Aegerion Pharmaceuticals Appoints Gregory Perry as Chief Financial Officer Jun 25 2015
Broadfin Capital Thinks ContraFect Corp (CFRX) Can Prevent 25% of Deaths Jun 22 2015
Edited Transcript of AEGR presentation 13-May-15 8:00pm GMT Jun 17 2015
Aegerion Pharmaceuticals Announces Key Additions to Medical Affairs and Drug Safety Jun 16 2015
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Jun 11 2015
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Jun 11 2015
Scopia Management returns an estimated 4.43% for May Jun 03 2015
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers May 29 2015
Aegerion Pharmaceuticals Announces Presentation at the Jefferies 2015 Healthcare Conference May 27 2015
Aegerion Pharmaceuticals Announces Presentation at the Jefferies 2015 Healthcare Conference May 27 2015
Aegerion's Juxtapid Successful in Phase III Japanese Study - Analyst Blog May 27 2015
Aegerion Pharmaceuticals Achieves Primary Endpoint in Phase III Study of Lomitapide in Japanese... May 26 2015
Aegerion Pharmaceuticals Achieves Primary Endpoint in Phase III Study of Lomitapide in Japanese... May 26 2015
AEGERION PHARMACEUTICALS, INC. Financials May 16 2015
CFO Moves: Arista Networks, 3D Systems, Aegerion Pharmaceuticals May 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK